Happy New Year from the Hepatitis B Foundation

As we welcome the new year, we would like to take a moment to express our gratitude to our community. Your strength, compassion and unwavering support continue to drive our mission forward.


Together, we remain committed to improving the lives of those affected by hepatitis B—no matter the challenges we face. Because of you, progress is possible, we have hope and voices are heard.

✨ Here’s to resilience, hope, and meaningful progress in the year ahead. Thank you for standing with us as we move into another year of impact.

Top U.S. health official visits our campus

(L-R) Dr. Chari Cohen, Rep. Brian Fitzpatrick, Dr. Jay Bhattacharya, CEO Lou Kassa and Dr. Ju-Tao Guo. 

(L-R), CEO Lou Kassa, Dr. Jay Bhattacharya and Dr. Jinghong Chang

The Hepatitis B Foundation recently welcomed NIH Director Jay Bhattacharya, MD, PhD, for a visit highlighting collaborative research and academic programs advancing public health and biomedical discovery.


Joined by U.S. Rep. Brian Fitzpatrick, Dr. Bhattacharya toured laboratories, met with scientists and participated in a roundtable discussion focused on NIH-supported research, drug development and training the next generation of biomedical innovators. The visit showcased the impact of sustained federal investment in research—including groundbreaking work on hepatitis B, liver cancer and antiviral therapies.


Leaders from our three organizations emphasized the importance of strong partnerships between government, research institutions and industry to translate scientific discovery into real-world solutions that improve public health.


Please read the full press release here.

International Quality of Life Month:

Take care of your health—and your liver

This month is a reminder that caring for your liver is a key aspect of protecting your health. Hepatitis B is a vaccine-preventable disease, and just a few shots can provide lifelong protection for you and your loved ones.


If you are living with chronic hepatitis B, know that the condition is manageable and treatable. With proper care and regular monitoring, you can expect to live a long, full life. A diagnosis may feel overwhelming at first—but you are not alone, and support is available.

Taking steps to prevent hepatitis B or manage it effectively is an important investment in your quality of life.

Foundation and Institute leaders played a key role at Hep-DART 2025

The Hepatitis B Foundation and Baruch S. Blumberg Institute made a strong impact at Hep-DART 2025, held Dec. 7–11 in Honolulu. This annual international meeting brings together experts to advance research and innovation across viral hepatitis, liver disease and cancer.


Dr. Chari Cohen, president of the Hepatitis B Foundation, chaired a Foundation-sponsored session on hepatitis B basic science, immunology and therapeutics, underscoring the Road to an HBV Cure.

Catherine Freeland, PhD, MPH

Associate Director of Public Health Research, Hepatitis B Foundation 

Dr. Catherine Freeland presented on: "Taking hepatitis B prevention, treatment and cure to Africa" where she focused on epidemiological data highlighting the substantial burden of hepatitis B on the continent.


Although there are barriers to overcome, efforts are underway to address these gaps, including the launch of the Africa Hepatitis B Advocacy Coalition by the Hepatitis B Foundation, which strengthens community capacity across more than 25 countries through a network of more than 200 partners.

 

Yanming Du, PhD

Professor, Baruch S. Blumberg Institute

Dr. Yanming Du of our sister organization the Blumberg Institute presented on: "Discovery of HS-83128: An Orally Bioavailable, Liver-Targeted Dihydroquinolizinone with In Vivo Efficacy Against HAV and HBV." He focused on optimization targeting liver-selective distribution.


By incorporating a recognition motif for the hepatocyte-specific solute carrier transporters OATP1B1 and OATP1B3, his team successfully designed DHQ-based compounds that serve as substrates for these transporters. Please read the full summary here.

Our presence at Hep-DART reflects a continued commitment to global collaboration, scientific leadership, and accelerating progress toward the elimination of hepatitis B.

The Foundation funds a valuable project in Nigeria's Delta State

A powerful new article highlights a pilot program in Nigeria’s Delta State, which is funded by the Hepatitis B Foundation, that is significantly increasing hepatitis B birth-dose vaccination, protecting newborns.



We’re proud to spotlight community leader, Prince Okinedo, one of our #BTheVoice storytellers and the founder of the Hepatitis Advocacy Foundation in Delta State — a true champion for hepatitis B prevention and community-led change. Please read the full article here.

The Hepatitis B Foundation is making a major, multiyear investment in a new program: African Hepatitis Advocacy Coalition. The Foundation is supporting hepatitis B elimination in Africa, where its staff has been working with strong local partners in more than 12 countries to develop models for prevention, education, testing and linkage to care. 

Real stories from people living with hepatitis B

Living with hepatitis B looks different for everyone—but early diagnosis, regular follow-up and access to treatment can make all the difference.


Susan learned she had hepatitis B during pregnancy, leading her family to get tested and treated. Today, her parents are cured, her husband is on long-term therapy, and all have healthy livers—she hopes that everyone can access care. Alex was diagnosed through community screening and began treatment when his condition changed, highlighting the importance of regular monitoring and accessible health systems.


Others’ experiences show the risks of delayed care. Jason, infected through a childhood transplant, was cured of hepatitis C but later faced a severe hepatitis B flare. Shane and Stanly both went years without consistent follow-up—resulting in liver cancer and cirrhosis. They both started treatment and made critical lifestyle changes.

Next B Informed virtual education discussion:

Boosting diverse HBV clinical trial participation

Please join us for a discussion on our newly published study: "Boosting diverse communities’ participation in clinical trials: What people living with hepatitis B must know."



Drawing on mixed-methods data from 10 U.S. communities, we will explore how access to accurate information and community-centered partnerships can improve research participation and inclusivity in hepatitis B clinical trials.

Tuesday, Jan. 20

3 p.m. EST

Hep B United is a national coalition established by the Hepatitis B Foundation and the Association of Asian Pacific Community Health Organizations (AAPCHO), to address and eliminate hepatitis B. Learn more here.

New webinar | Protecting infants from day one: Evidence for HepB birth dose impact and how clinicians can build parent confidence

This webinar will highlight four decades of evidence showing how universal newborn hepatitis B vaccination helped eliminate HBV transmission and childhood liver cancer among Alaska Native communities. The session will also provide practical strategies for talking with parents about the HepB birth dose, including explaining the vaccine schedule, addressing common concerns, and fostering confidence in early immunization.


Speakers

📆 Tuesday, Feb. 3

⌚ 3:30 - 4:30 p.m. EST

  • Brian McMahon, MD, Director, Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium
  • Joanna Parga-Belinkie, MD, Neonatologist, Children's Hospital of Philadelphia 

Fact checked: U.S. vaccine recommendations protect children

The American Academy of Pediatrics (AAP) recently reaffirmed that U.S. childhood vaccine recommendations are safe, effective and evidence-based. These guidelines are carefully designed to protect children at the ages when they are most vulnerable to serious diseases and when vaccines work best with their immune systems.

Vaccine schedules may differ between countries due to variations in disease risk, health systems and vaccine availability—but there is no medical reason to delay or skip recommended vaccines in the U.S. Extensive research shows that routine childhood immunizations prevent millions of illnesses and deaths while saving billions in health care costs. Read more from the AAP here.

New blog | Beyond the Liver:

The broader impact of living with chronic hepatitis B

New research is revealing that chronic hepatitis B affects far more than the liver. While hep B is well known as a leading cause of cirrhosis and liver cancer, studies now show it can also raise the risk of cancers in other parts of the body. Researchers have found that HBV can be present in organs like the kidneys and pancreas, where long-term inflammation may contribute to cancer development and other serious conditions such as kidney disease and blood disorders. Please read the full blog here.

A new episode of our podcast is now live!

From exposure to empowerment: Bruno’s journey with hepatitis B

In this episode, Bright and Anousha speak with Bruno D’Amato, a hepatitis B advocate whose diagnosis came decades after an unexpected hospital exposure.


Symptom-free for years, Bruno’s routine tests revealed liver fibrosis, prompting life-changing treatment. He shares his journey from silent infection to healing and the importance of regular monitoring, self-care and hope. 


Please listen to the podcast here.

Bruno, #justB storyteller

Journal article of the month

Adherence to antiviral treatment among people living with chronic hepatitis B:

A global survey


World Journal of Virology. 2025; 14(4): 110951

LINK

Block S, Ibrahim Y, Cohen C

This study is based on survey responses from 614 people living with chronic hepatitis B infections around the world.


The authors wrote: "This study adds new data and can inform future treatment guidelines to better align with patients’ lived experiences and support effective programmatic strategies aimed at optimizing treatment adherence and improving health outcomes for people living with hepatitis B worldwide."


The results showed: "Overall, 81% of respondents reported high adherence to hepatitis B treatment... Among participants with low adherence, 79% described physical functioning as a challenge." Other obstacles to consistent, long-term treatment reported by these patients were affordability (60%), health care service acceptability (53%) and psychological functioning (41%).

Learn more about our research and education programs at www.hepb.org

The Hepatitis B Foundation is a global nonprofit organization dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide. Our commitment includes funding focused research, promoting disease awareness, supporting immunization and treatment initiatives, and serving as the primary source of information for patients and their families, the medical and scientific community and the general public.

Facebook  Twitter  Instagram  Youtube